ONMD PRESS-RELEASE SEC Filing Analysis

Latest settled — T+20d

ONMD ▲ +8.30% at T+20d

NEUTRAL call ✓ call won +8.30% · α vs SPY +2.26% · entry $0.8190 → $0.8870

Next anchor: T+60d in 2d

Last close $0.6900 (close Jun 8) · -15.75% from $0.8190 entry

Entry anchored
Mar 17, 03:59 PM ET
via Databento tick

T+1d

-2.93%

call -2.93% · α -2.66%

$0.7950

settled 3mo ago

T+5d

+5.74%

call +5.74% · α +6.45%

$0.8660

settled 3mo ago

T+20d

+8.30%

call +8.30% · α +2.26%

$0.8870

settled 8w ago

T+60d

—

call — · α —

—

in 2d

Price Chart

Loading chart...

Executive Summary

OneMedNet Corporation (ONMD) announced a strategic collaboration with Navidence to integrate Navidence's Computable Operational Definitions (CODefs) into OneMedNet's iRWD™ platform, aiming to streamline real-world data access for life sciences research. The partnership targets efficiency, cost savings, and regulatory readiness in drug development, AI training, and real-world evidence generation, positioning OneMedNet to capture more value in the rapidly growing $1.88B real-world data market.

Actionable Insight

Monitor for future customer wins, commercial adoption of the integrated platform, or expanded use in AI training and regulatory submissions; absence of near-term financials limits immediate trading catalysts.

Key Facts

OneMedNet is collaborating with Navidence to integrate CODefs into its iRWD™ platform powered by Palantir Foundry.
The integration aims to improve cohort definition, data matching, and study execution speed for pharma and CROs.
No financial terms, revenue projections, or customer commitments were disclosed.
Forward-looking benefits include efficiency gains, cost savings, and regulatory advantages, but no quantified financial impact is provided.
Real-world data market projected to grow from $1.88B in 2025 to $6.37B by 2034 at 14.54% CAGR.

Financial Impact

Potential long-term revenue upside in a growing $6.37B market by 2034, but no immediate financial impact disclosed

revenueoperating efficiencymarket positioning

Risk Factors

Execution risk: Integration success depends on technical and commercial adoption by pharma/CRO clients.
Market competition: Other RWD providers may offer similar standardization tools.
No revenue or earnings impact disclosed — benefits are speculative and forward-looking.

Market Snapshot

Exchange

Nasdaq

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3258189

3 reports for ONMD

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for ONMD — sortable, filterable
	Type				Now
Apr 6, 2026 9w ago	Press Release BULLISH ★ 8/10	$0.9520 $1.05	▲ +10.29%	▲ +1.31%	$0.6900 (−27.52%)
Apr 1, 2026 9w ago	Press Release NEUTRAL ★ 4/10	$0.8440 $1.08	▲ +27.96%	▲ +18.24%	$0.6900 (−18.25%)
Mar 18, 2026 11w ago	Press Release MIXED ★ 5/10	$0.8190 $0.8870	▲ +8.30%	▲ +2.26%	$0.6900 (−15.75%)

US Market Status

Market Closed — Opens in 8h 12m

Related Tickers

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access